SCHEMBL368639

SCHEMBL368639

COC(=O)c1nnc(N)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.50
HTT P42858 1/20 0.50
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TP53 P04637 2/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CES1 P23141 1/20 0.40
ALDH1A1 P00352 6/20 0.40
POLB P06746 3/20 0.39
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
F2 P00734 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
PKM P14618 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283280 0.79 ALDH1A1 (0.52) HSD17B10HTTNPC1RAB9AALOX15
SCHEMBL12536873 0.79 ALDH1A1 (0.44) HSD17B10HTTNPC1RAB9ATP53
SCHEMBL13800945 0.79 HSD17B10 (0.40) HSD17B10HTTNPC1RAB9ATP53
SCHEMBL18352875 0.78 CES1 (0.42) HSD17B10HTTTP53KMT2AMEN1
SCHEMBL12536605 0.78 ALDH1A1 (0.44) HSD17B10HTTNPC1RAB9ATP53
SCHEMBL3910072 0.78
SCHEMBL7453197 0.77 SMN1; SMN2 (0.43) HSD17B10NPC1RAB9ATP53KMT2A
SCHEMBL13800984 0.76 MAPT (0.44) HSD17B10HTTNPC1RAB9ATP53
SCHEMBL952705 0.75 HSD17B10 (0.43) HSD17B10HTTTP53ALOX15KMT2A
SCHEMBL27264408 0.75 TSHR (0.42) HSD17B10HTTNPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025035108-A2 INHIBITORS OF PARG ARASE THERAPEUTICS INC. (US) 2025-02-13 WO disclosed
WO-2024245310-A1 THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2024-12-05 WO disclosed
US-11530205-B2 GLP-1 receptor modulators RECEPTOS LLC (US) 2022-12-20 US disclosed
EP-3615524-B1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC (US) 2022-11-09 EP disclosed
WO-2022095989-A1 P300 INHIBITORS AND USE THEREOF IN MEDICINE 贝达药业股份有限公司 2022-05-12 WO disclosed
US-20210371409-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2021-12-02 US disclosed
EP-3615524-A1 NOVEL GLP-1 RECEPTOR MODULATORS Celgene International II Sàrl (CH) 2020-03-04 EP disclosed
WO-2018200833-A1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2018-11-01 WO disclosed
US-9532989-B2 Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-01-03 US disclosed
US-20150374697-A1 ORGANIC COMPOUNDS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2015-12-31 US disclosed
US-9066948-B2 Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2015-06-30 US disclosed
US-20130251761-A1 ORGANIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-09-26 US disclosed
EP-2593106-A1 ORGANIC COMPOUNDS Rockefeller University (US) 2013-05-22 EP disclosed
WO-2012009688-A1 ORGANIC COMPOUNDS ROCKEFELLER UNIVERSITY (US) 2012-01-19 WO disclosed
WO-1999031096-A1 PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS SHAMAN PHARMACEUTICALS, INC. (US) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371409-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GCGR HSD17B10 3262/4885HTT 1821/4885NPC1 2298/4885
US-11530205-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR HSD17B10 3431/4885HTT 1726/4885NPC1 2088/4885
US-20150374697-A1 ORGANIC COMPOUNDS PLAT, ICAM1, VCAM1 HSD17B10 1526/4885HTT 1286/4885NPC1 601/4885
US-20130251761-A1 ORGANIC COMPOUNDS PLAT, ICAM1, VCAM1 HSD17B10 1526/4885HTT 1286/4885NPC1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.